A Phase III, Randomized, Double-blind, Placebo Controlled, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Pirfenidone in Subjects With Dermatomyositis Interstitial Lung Disease (Dm-ILD)
Latest Information Update: 05 May 2021
At a glance
- Drugs Pirfenidone (Primary)
- Indications Dermatomyositis; Interstitial lung diseases
- Focus Registrational; Therapeutic Use
- Sponsors Beijing Continent Pharmaceutical
Most Recent Events
- 05 Mar 2019 New trial record